Clinical Trial Update: Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating an EGFR inhibitor in combination with gemcitabine and oxaliplatin for advanced biliary tract cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Gemcitabine (Gemcitabine)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Advanced Biliary Cancer | Phase 2 | Status: COMPLETED